All In Biotech

Drug Trial Radar · NCT05862337

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study of Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection in Patients With High Risk of Relapse After Radical Surgery or Ablation of Hepatocellular Carcinoma (HCC).

Last checked: Nov 20, 2026Latest source record: May 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

480

Planned (sponsor's estimate)

Start

May 10, 2023

Primary completion

Aug 2024

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
May 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study was to evaluate the efficacy of anlotinib hydrochloride capsules combined with penpulimab injection (test group) versus placebo (control group) for adjuvant therapy after radical surgery or ablation in HCC patients with high risk of recurrence by assessing recurrence-free survival (RFS).

Conditions

  • Hepatocellular Carcinoma

Interventions

  • Anlotinib hydrochloride capsules, Penpulimab injectionDrug

    Anlotinib hydrochloride capsules is a multitargeted receptor tyrosine kinase inhibitor. Penpulimab injection is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1).

  • Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placeboDrug

    placebo control, no active substance.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence-free survival (RFS)Time frame: Baseline up to 3 years.

Locations

67 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China · Recruiting

  • Anhui Provincial Hospital

    Hefei, Anhui, China · Recruiting

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Not yet recruiting

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Friendship hospital of Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing YouAn Hospital,Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Chongqing University Three Gorges Hospital

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Mengchao Hepatobiliary Hospital of Fujian Medical

    Fuzhou, Fujian, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Gansu Provincial Cancer Hospital

    Lanzhou, Gansu, China · Recruiting

  • Lanzhou University First Hospital

    Lanzhou, Gansu, China · Not yet recruiting

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China · Not yet recruiting

  • Gansu Provincial Hospital

    Lanzhou, Gansu, China · Recruiting

  • Guangdong People's Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, Guangxi, China · Not yet recruiting

  • Guizhou Provincial People'S Hospital

    Guiyang, Guizhou, China · Recruiting

  • The Affiliated Cancer Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Not yet recruiting

  • Affiliated Hospital Of Zunyi Medical University

    Zunyi, Guizhou, China · Recruiting

  • Hainan Provincial People's Hospital

    Haikou, Hainan, China · Recruiting

  • The Second Affiliated Hospital of Hainan Medical University

    Haikou, Hainan, China · Recruiting

  • Affiliated Cancer Hospital of Harbin Medical University

    Harbin, Heilongjiang, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • Hunan Provincial People's Hospital

    Changsha, Hunan, China · Not yet recruiting

  • The Third Xiang Ya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Chifeng Municipal Hospital

    Chifeng, Inner Mongolia, China · Recruiting

  • The First People's Hospital of Changzhou

    Changzhou, Jiangsu, China · Recruiting

  • Jiangsu Province People's Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, China · Recruiting

  • Nantong Tumor Hospital

    Nantong, Jiangsu, China · Not yet recruiting

  • Ganzhou People's Hospital

    Ganzhou, Jiangxi, China · Recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.